Streetbeat News

Price Targets

CDW

Barclays analyst Mark Moskowitz maintains an Equal-Weight rating on CDW (NASDAQ:CDW) and raises the price target from $216 to $219.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:04 pm

GOOS

Barclays analyst Adrienne Yih has maintained an Equal-Weight rating on Canada Goose Holdings (NYSE:GOOS) and lowered the price target from $18 to $11.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:02 pm

EAT

Barclays analyst Jeffrey Bernstein maintains an Equal-Weight rating on Brinker International (NYSE:EAT) and raises the price target from $34 to $36.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:00 pm

BMRN

Barclays analyst Gena Wang has maintained an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowered the price target from $125 to $111.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:59 pm

BYND

Barclays analyst Benjamin Theurer maintains an Underweight rating on Beyond Meat (NASDAQ:BYND) and has lowered the price target from $9 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:58 pm

BALY

Barclays analyst Brandt Montour has maintained an Equal-Weight rating on Ballys (NYSE:BALY) and lowered the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:57 pm

SEDG

Exane BNP Paribas analyst Moses Sutton has downgraded SolarEdge Technologies (NASDAQ:SEDG) from Outperform to Neutral and set a price target of $71.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:50 pm

APO

Barclays analyst Benjamin Budish maintains an Overweight rating on Apollo Global Management (NYSE:APO) but lowers the price target from $109 to $106.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:40 pm

EGHT

Barclays analyst Ryan Macwilliams maintains an Equal-Weight rating on 8x8 (NASDAQ:EGHT) and lowers the price target from $4 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:39 pm

HUM

Stephens & Co. analyst Scott Fidel maintains an Overweight rating on Humana (NYSE:HUM) but lowers the price target from $575 to $570.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 2:32 pm